Carta Healthcare Raises $18.25 Million for Advanced AI in Clinical Data Management
On May 7, 2025, Carta Healthcare announced a significant milestone, securing $18.25 million in Series B1 funding. This investment marks a pivotal step for the company, further solidifying its position as a leader in AI-powered clinical data abstraction. As healthcare systems and life sciences organizations increasingly seek innovative solutions, Carta Healthcare is well-positioned to deliver insights that can transform operational efficiencies and enhance patient care.
Led by UPMC Enterprises, the investment saw participation from various strategic partners, including MemorialCare Innovation Fund, Rex Health Ventures, Tampa General Hospital Ventures, and several existing investors. Brent Burns, UPMC's Executive Vice President, emphasized the importance of leveraging AI to streamline clinical data abstraction, a process traditionally viewed as labor-intensive and time-consuming. This funding aims to alleviate such challenges, allowing healthcare providers to match patients with clinical trials more efficiently.
The fresh capital will support Carta Healthcare in expanding its customer base, particularly within the fast-evolving life sciences sector. This follows the company's 2024 acquisition of Realyze Intelligence, which enhanced its capabilities in managing structured and unstructured data - a leap forward in identifying patients for research studies and trials.
Brent Dover, CEO of Carta Healthcare, asserted that this funding reflects a growing validation of their mission to harness clinical data more effectively. The robust backing from leading health systems not only enables Carta to scale its operations but also opens the door for innovations, ultimately enhancing the quality of healthcare services offered.
In a similar vein, Navid Farzad, Managing Partner at Frist Cressey Ventures, reiterated that effective clinical data abstraction is crucial for health improvement. Since their initial involvement, Carta Healthcare has consistently focused on automating the data abstraction process, which not only generates high-quality clinical data but also enhances return on investment by cutting down labor costs associated with data handling.
Memorial Hermann Health System has echoed this sentiment, with Feby Abraham, its Chief Strategy Officer, highlighting their commitment to investing in technologies that cater to the diverse needs of patients in the Greater Houston area. By collaborating with Carta Healthcare, they aim not only to improve current healthcare delivery but also to foster a healthier community for future generations.
Founded in 2017, Carta Healthcare is pioneering various innovative approaches within clinical data management and healthcare analytics. Their proficiency lies in merging artificial intelligence with clinical expertise, automating the data collection and analytical processes, and subsequently offering actionable insights that can drive quality improvement initiatives.
Carta Healthcare's pricing model revolves around delivering measurable value, demonstrated through consistent growth metrics. As the company seeks to optimize its workforce and expand its reach, the insights gained from strategic investors will elevate their capacity to seize substantial market opportunities. CFO Lucas Tanner reassured stakeholders about the firm’s financial stability and pointed out that this new round of funding will empower them to address the rising demand in the healthcare sector more effectively.
With a focus on operational efficiency powered by AI-driven data management solutions, Carta Healthcare is paving the way for the future of healthcare analytics. As they continue to innovate and expand their solutions, the partnership with esteemed health systems sets a promising trajectory for improved healthcare delivery nationwide. For further information on their solutions, visit www.carta.healthcare.
Led by UPMC Enterprises, the investment saw participation from various strategic partners, including MemorialCare Innovation Fund, Rex Health Ventures, Tampa General Hospital Ventures, and several existing investors. Brent Burns, UPMC's Executive Vice President, emphasized the importance of leveraging AI to streamline clinical data abstraction, a process traditionally viewed as labor-intensive and time-consuming. This funding aims to alleviate such challenges, allowing healthcare providers to match patients with clinical trials more efficiently.
The fresh capital will support Carta Healthcare in expanding its customer base, particularly within the fast-evolving life sciences sector. This follows the company's 2024 acquisition of Realyze Intelligence, which enhanced its capabilities in managing structured and unstructured data - a leap forward in identifying patients for research studies and trials.
Brent Dover, CEO of Carta Healthcare, asserted that this funding reflects a growing validation of their mission to harness clinical data more effectively. The robust backing from leading health systems not only enables Carta to scale its operations but also opens the door for innovations, ultimately enhancing the quality of healthcare services offered.
In a similar vein, Navid Farzad, Managing Partner at Frist Cressey Ventures, reiterated that effective clinical data abstraction is crucial for health improvement. Since their initial involvement, Carta Healthcare has consistently focused on automating the data abstraction process, which not only generates high-quality clinical data but also enhances return on investment by cutting down labor costs associated with data handling.
Memorial Hermann Health System has echoed this sentiment, with Feby Abraham, its Chief Strategy Officer, highlighting their commitment to investing in technologies that cater to the diverse needs of patients in the Greater Houston area. By collaborating with Carta Healthcare, they aim not only to improve current healthcare delivery but also to foster a healthier community for future generations.
Founded in 2017, Carta Healthcare is pioneering various innovative approaches within clinical data management and healthcare analytics. Their proficiency lies in merging artificial intelligence with clinical expertise, automating the data collection and analytical processes, and subsequently offering actionable insights that can drive quality improvement initiatives.
Carta Healthcare's pricing model revolves around delivering measurable value, demonstrated through consistent growth metrics. As the company seeks to optimize its workforce and expand its reach, the insights gained from strategic investors will elevate their capacity to seize substantial market opportunities. CFO Lucas Tanner reassured stakeholders about the firm’s financial stability and pointed out that this new round of funding will empower them to address the rising demand in the healthcare sector more effectively.
With a focus on operational efficiency powered by AI-driven data management solutions, Carta Healthcare is paving the way for the future of healthcare analytics. As they continue to innovate and expand their solutions, the partnership with esteemed health systems sets a promising trajectory for improved healthcare delivery nationwide. For further information on their solutions, visit www.carta.healthcare.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.